Research Article
Effect of Moxibustion on HIF-1α and VEGF Levels in Patients with Rheumatoid Arthritis
Table 1
Baseline characteristics.
| | Treatment group (n = 20) | Control group (n = 17) | value |
| Characteristic | | | | Gender, male/female | 1/19 | 2/15 | 0.452 | Age (y), mean (SD) | 46.85 (11.30) | 49.41 (10.37) | 0.48† | Disease duration (y), mean (SD) | 5.44 (4.05) | 6.34 (5.11) | 0.55† | Clinical symptoms | | | | VAS score, mean (SD) | 6.60 (1.60) | 6.71 (1.57) | 0.84† | Morning stiffness score, mean (SD) | 3.60 (1.79) | 3.89 (1.11) | 0.56† | Tenderness index, mean (SD) | 2.79 (1.43) | 2.77 (1.38) | 0.77† | Swelling index, mean (SD) | 2.67 (1.84) | 2.72 (1.64) | 0.42† | DAS28 score, mean (SD) | 6.43 (1.23) | 6.87 (0.96) | 0.25† | RA-associated serum markers | | | | ESR (mm/60 min), mean (SD) | 54.75 (30.94) | 57.76 (31.77) | 0.87Δ | CRP (mg/L), mean (SD) | 15.04 (30.18) | 22.14 (30.23) | 0.13Δ | RF (IU/ml), mean (SD) | 167.56 (192.89) | 185.81 (213.04) | 0.58Δ |
|
|
value by X2 test. †P value by independent samples t-test. ΔP value by Mann‐Whitney U test. |